Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Scientific References Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Effective weight management goes beyond appearance
Native GLP-1 has a short half-life of 12 min owing to rapid degradation by dipeptidyl peptidase-4 (DPP-4) [15]
fenfluramine was subsequently withdrawn from the US market in fall of 1997
Outcomes remain highly uncertain and hinge on uptake, effectiveness, persistency, and any benefits beyond BMI reduction so insurers should monitor this fast-moving landscape and consider implications for trend assumptions, lapse/anti-selection risk, underwriting, and claims
US$ 25.61
US$ 26.34
US$ 23.50
